| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: ACUS |
| Security Type |
Common Stock |
| Lead Underwriter |
SG Cowen Securities Corp |
| Days In Registration |
62 |
| Date Filed |
6-Aug-2003 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Develop new drugs and improved formulations of existing drugs using a proprietary porous microparticle technology |
| Revenue |
- |
| Net Income |
-$21.9M |
| Shares Outstanding (post-offering) |
14.27M |
| Contact |
- |
| Number of Employees |
53 |
|
| Original Filing Information |
| US |
| Shares Filed |
3.75M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
562.5K |
| File Amount |
$52.5M |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
Current Filing Information
(Amended 6-Oct-2003) |
|
US |
|
Shares Filed |
3.75M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
3.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$52.5M |
| · % Change from Original |
0.0 |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
|
